IL313491A - Managbodies directed to P53 tumor antigens and methods of use - Google Patents

Managbodies directed to P53 tumor antigens and methods of use

Info

Publication number
IL313491A
IL313491A IL313491A IL31349124A IL313491A IL 313491 A IL313491 A IL 313491A IL 313491 A IL313491 A IL 313491A IL 31349124 A IL31349124 A IL 31349124A IL 313491 A IL313491 A IL 313491A
Authority
IL
Israel
Prior art keywords
manabodies
targeting
methods
tumor antigens
antigens
Prior art date
Application number
IL313491A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of IL313491A publication Critical patent/IL313491A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL313491A 2021-12-16 2022-12-15 Managbodies directed to P53 tumor antigens and methods of use IL313491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163290353P 2021-12-16 2021-12-16
PCT/US2022/053065 WO2023114430A1 (en) 2021-12-16 2022-12-15 Manabodies targeting p53 tumor antigens and methods of using

Publications (1)

Publication Number Publication Date
IL313491A true IL313491A (en) 2024-08-01

Family

ID=86773477

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313491A IL313491A (en) 2021-12-16 2022-12-15 Managbodies directed to P53 tumor antigens and methods of use

Country Status (10)

Country Link
US (1) US20250034252A1 (https=)
EP (1) EP4448583A4 (https=)
JP (1) JP2024546923A (https=)
KR (1) KR20240127981A (https=)
CN (1) CN118541396A (https=)
AU (1) AU2022415459A1 (https=)
CA (1) CA3242393A1 (https=)
IL (1) IL313491A (https=)
MX (1) MX2024007456A (https=)
WO (1) WO2023114430A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106598A1 (en) * 2023-11-13 2025-05-22 Clasp Therapeutics, Inc. Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294183B2 (en) * 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
GB201617564D0 (en) * 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
WO2021127184A1 (en) * 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING

Also Published As

Publication number Publication date
CN118541396A (zh) 2024-08-23
JP2024546923A (ja) 2024-12-26
MX2024007456A (es) 2024-09-10
CA3242393A1 (en) 2023-06-22
WO2023114430A1 (en) 2023-06-22
EP4448583A4 (en) 2025-12-17
KR20240127981A (ko) 2024-08-23
AU2022415459A1 (en) 2024-07-04
US20250034252A1 (en) 2025-01-30
EP4448583A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
EP3574018A4 (en) CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
ZA202102381B (en) Macrophage capable of targeting tumor cell and preparation method thereof
ZA202006905B (en) Gene therapy constructs and methods of use
EP4077370A4 (en) MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE
IL284645A (en) Therapeutic RNA and Anti PD1 antibodies for the treatment of solid cancer tumors in advanced stages
SG11202104362SA (en) Plasmid constructs for treating cancer and methods of use
IL279633A (en) Immunoconjugates targeting ADAM9 and methods of using them
EP4519323A4 (en) Tumor activated antibodies targeting trop2 and uses thereof
EP4007640A4 (en) CANCER COMBINATION THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPY AGENTS
IL278225A (en) Anti SEZ6 antibody drug conjugates and methods of use
EP4146704A4 (en) ANTIBODIES DIRECTED AGAINST CLEC12A AND USE THEREOF
PT4200018T (pt) Anticorpos anti-par-2 e métodos de uso dos mesmos
IL304245A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment
IL280000A (en) Formulations for reducing tumors and methods of using them
IL313491A (en) Managbodies directed to P53 tumor antigens and methods of use
EP4041718A4 (en) PHOSPHOLIPIDE-FLVAGLIN CONJUGATES AND METHOD FOR THE USE THEREOF FOR TARGETED CANCER THERAPY
EP4125946A4 (en) MONOCLONAL ANTIBODIES TARGETING HSP70 AND THEIR THERAPEUTIC USES
IL315828A (en) Antibodies against SIRP-ALPHA and their uses
IL308260A (en) Antibodies against Tigit and methods of using them
HK40116517A (en) Manabodies targeting p53 tumor antigens and methods of using
IL281767A (en) CD137-directed antibodies and methods of using them
IL326345A (en) Drug conjugates, methods of their preparation and uses
HK40076153A (en) Manabodies targeting tumor antigens and methods of using
HK40107667A (en) Methods and materials for targeting tumor antigens
EP4314054A4 (en) SINGLE-DOMAIN ANTI-EGFR ANTIBODIES AND THERAPEUTIC CONSTRUCTS